You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, up 36%, and $46.2 million in cash after $22 million of ATM proceeds. Unicure submitted AMT-130's BLA to the FDA, while the company targets five Eraflow milestones and commercial launches in 2027.
ClearPoint Neuro, Inc. reported $35.1 million revenue for the nine months ended September 30, 2026, up 32%, while net loss increased 60%. Cash was $46.2 million, sufficient for at least the next twelve months.
ClearPoint Neuro reported third-quarter revenue of $12.1 million, up 36%, and now estimates 2026 revenue of $48.0 million to $50.0 million. It ended September 30, 2026 with $46.2 million in cash and cash equivalents.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Q3 revenue grew 36% to $12.1 million, including 59% growth in neurosurgery navigation and therapy and 68% growth in capital equipment and software, while gross margin declined to 58% and net loss widened to $7.460 million. The company now estimates 2026 revenue of $48.0 million to $50.0 million, feels good about mid-teens base-business growth for 2027, and advanced its drug-delivery and spine-laser roadmap through a partner’s Huntington’s disease BLA submission and a five-year NCI grant.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active Global Centers (installed base) | 175 | August 2026 | — |
| Active installed base | 150 | current | — |
| Active Pharma Partners | 60 | current | — |
| Biologics and drug delivery revenue | 4M | three months ended June 30, 2026 | — |
| Capital equipment and software revenue | 1.3M | three months ended June 30, 2026 | — |
| Employees | 160 | current | — |
| Gross margin | 62% | three months ended June 30, 2026 | — |
| Neurosurgery navigation and therapy revenue | 5.6M | three months ended June 30, 2026 | — |
| PATENTS ISSUED | 130 | as of, and for the quarter ended June 30, 2026 | — |
| Procedures used to date | 10,000 | to date | — |
| Programs accepted for FDA expedited review | 10 | current | — |
| Share of total sales from customers paying a quarterly fee (software, clinical services and mark | 6% | the three months ended June 30, 2026 filing | -25.0% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLPT
this stock
ClearPoint Neuro, Inc.
|
$271.82M | -38.0% | +17.8% | — | 13.4% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
ClearPoint Neuro, Inc. reported $35.1 million revenue for the nine months ended September 30, 2026, up 32%, while net loss increased 60%. Cash was $46.2 million, sufficient for at least the next twelve months.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLPT | -1.4% | -6.5% | -28.3% | -20.5% | -38.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.0% | -5.3% | -28.8% | -20.3% | -48.6% |
